During the past decade, Fakultni nemocnice Plzen conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 21 clinical trials were completed, i.e. on average, 48.8% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 17 clinical trials were completed. i.e. 85% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fakultni nemocnice Plzen" #1 sponsor was "Janssen Research & Development, LLC" with 8 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "Amgen" with 5 trials sponsored, "Bayer" with 5 trials sponsored and "Celgene" with 5 trials sponsored. Other sponsors include 34 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fakultni nemocnice Plzen" #1 collaborator was "Central European Myeloma Study Group" with 1 trials as a collaborator, "DSMM (Deutsche Studiengruppe Multiples Myelom)" with 1 trials as a collaborator, "Deutsche Krebshilfe e.V., Bonn (Germany)" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "European Myeloma Network" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Fakultni nemocnice Plzen" are "Multiple Myeloma" (6 trials), "Venous Thromboembolism" (4 trials), "Crohn Disease" (3 trials), "Psoriasis" (3 trials) and "Atrial Fibrillation" (2 trials). Many other conditions were trialed in "Fakultni nemocnice Plzen" in a lesser frequency.

Most popular intervention types in "Fakultni nemocnice Plzen" are "Drug" (53 trials), "Other" (9 trials), "Biological" (4 trials), "Device" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Dexamethasone" (6 trials), "Lenalidomide" (4 trials), "Bortezomib" (3 trials) and "Daratumumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Fakultni nemocnice Plzen" are 65 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Fakultni nemocnice Plzen". 2 are not yet recruiting, 21 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in Fakultni nemocnice Plzen, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Fakultni nemocnice Plzen, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".